Self Employed Tax Software UK: Why Freelancers and Sole Traders Are Switching to Digital Filing

With Many individuals are seeking software that simplifies tax filing while ensuring full compliance with HMRC requirements. Manual spreadsheets and paper-based calculations are being replaced by real-time, automated systems that give users visibility over their tax position throughout the year. Among the platforms gaining traction is Pie, a UK-based digital tax app built specifically to support self-employed individuals with modern income needs.

LONDON, United Kingdom - February 19, 2026 - Demand for self employed tax software UK has surged as freelancers, contractors and sole traders increasingly turn to digital tools to manage their self assessment returns.

With self employment continuing to play a major role in the UK economy, many individuals are seeking software that simplifies tax filing while ensuring full compliance with HMRC requirements.

Manual spreadsheets and paper-based calculations are being replaced by real-time, automated systems that give users visibility over their tax position throughout the year.

Among the platforms gaining traction is Pie, a UK-based digital tax app built specifically to support self-employed individuals with modern income needs.

Why Self Employed Workers Need Dedicated Tax Software

Self employed taxpayers face unique reporting requirements. Unlike PAYE employees, they must track income, record expenses, calculate profits and manage payments independently.

Modern self employed tax software UK solutions typically provide:

• Real-time income and expense tracking

• Automatic tax calculations

• Support for allowable business expenses

• Secure digital record keeping

• Direct online submission aligned with HMRC systems

These features reduce errors, improve accuracy and help avoid unexpected tax bills.

“Self employment offers freedom, but tax responsibilities can feel complex,” said Tommy Mcnally, Founder of Pie. “Good tax software gives sole traders clarity and control over their finances.”

Designed for Today’s Independent Workforce

The UK’s self-employed workforce includes creatives, consultants, tradespeople, online sellers and gig economy workers. Many now earn income from multiple sources alongside their primary business activity.

Pie’s platform supports:

• Sole trader income

• Side income streams

• Rental property earnings

• Dividends and bank interest

• Capital gains

By consolidating these income types within one digital dashboard, users can manage their entire tax return without switching between systems.

Supporting HMRC’s Digital Future

As Making Tax Digital continues to shape compliance standards, self employed tax software UK is becoming essential. Digital record keeping and structured online submission are increasingly expected.

Software that aligns with HMRC requirements while remaining simple to use is now central to the self-employed filing process.

A Simpler Way to File

Self-employed individuals are no longer asking whether to use tax software — they are asking which platform offers the most clarity, accuracy and ease of use.

Pie’s mission reflects that shift:

“It’s your money. Claim it.”

Self-employed individuals across the UK looking for reliable, HMRC-compliant tax software can learn more at:

https://pie.tax

For enquiries or support: help@pie.tax

About Pie

Pie Money Limited is a UK fintech company dedicated to simplifying tax filing for individuals and small businesses. Its digital platform provides real-time tax calculations, multi-income support and secure HMRC submission, helping self-employed workers file with confidence.

Media Contact
Company Name: Pie Money Limited
Contact Person: Tommy Mcnally
Email:Send Email
Address:77 Lower Camden Street
City: Dublin 2
State: D02 XE80 Ireland
Country: United Kingdom
Website: https://pie.tax

CivicMail.org Reinvents Postcard Campaigns for Grassroots Advocacy

CivicMail.org aims to bring civic engagement back to basics through the power of pen, paper, and postage.

CivicMail.org has announced its launch to help Americans send real, physical postcards to their elected officials with just a few clicks, delivering personalized messages directly to the desks of decision-makers at the local, state, and federal levels.

Research shows that physical mail carries more weight with elected officials than petitions, emails, or tweets. In moments of crisis or debate, one tangible message can influence decisions or spark hundreds more. CivicMail.org offers a simple way for busy people to participate in democracy, even if they’ve never called on a representative before.

For just $3 per postcard, users can choose a campaign issue, personalize a message, and send it to their elected representatives without ever touching an address book, stamp, or envelope. The service prints, addresses, and mails the postcard (first class) on the sender’s behalf, turning online passion into offline pressure.

“I built this platform out of frustration that elected officials are not listening to their constituents. That’s largely because digital noise is easy to ignore. But a stack of handwritten postcards on a lawmaker’s desk? That gets noticed,” said Patrick Sweeney, founder of CivicMail.org. “We built this platform so that people can speak up quickly, affordably, and effectively and know their voice is landing somewhere that matters.”

CivicMail.org is designed for both individuals and advocacy organizations. Users can:

- Browse or join active campaigns on key issues.- Send personalized postcard messages.

- Create and send postcards to their local, state, and federal officials based on their address.

This isn’t a petition platform. When someone signs a petition, their name is added to a list that may or may not ever be meaningfully reviewed. With CivicMail.org, a message is sent directly to the elected official as a real, individual communication that offices track and count. That distinction matters. Lawmakers respond to constituent contact, not just aggregated signatures.

CivicMail.org turns passive agreement into active participation. Instead of simply adding their name, the user adds their voice and when thousands of voices arrive together, they create real pressure.

CivicMail.org can be used for a broad range of issues. From education and libraries to voting policy, government accountability, and local community priorities. The platform does not dictate what users advocate for; instead, it provides the infrastructure for civic participation.

“Democracy works best when people participate consistently, not just during elections,” Sweeney added. “CivicMail makes it easier to show up and be heard.”

The platform is now live and available nationwide.

To learn more or start sending postcards to elected officials, visit https://civicmail.org/

Follow @civicmail on social media to see which issues are trending and which voices are rising.

For any inquiry, send an email to info@civicmail.org

About Patrick Sweeney, Founder of CivicMail.org:

Patrick "PC" Sweeney is the owner and founder of CivicMail.org and is the Digital Director of EveryLibrary. He was awarded Library Journal’s “Movers and Shakers” award in 2015 for his library advocacy work. He is co-author of “Winning Elections and Influencing Politicians for Library Funding” as well as “Before the Ballot: Building Support for Library Funding.” He was recognized with a “40 Under 40” award by the American Association of Political Consultants for his work fighting for libraries at EveryLibrary. He is a lecturer at the San Jose Information School, where he teaches courses on politics and libraries. He is active across social media as PC Sweeney.

About CivicMail.org:

CivicMail.org is a civic tech platform making it easier than ever to contact lawmakers through personalized, printed postcards. We believe real messages create real pressure and real change.

Media Contact
Company Name: CivicMail
Contact Person: Patrick Sweeney
Email:Send Email
Phone: (410) 204-4375
City: Baltimore
State: Maryland
Country: United States
Website: CivicMail.org

No Backup - A Set Up and More Delivers a Courageous Reckoning with Power, Prejudice, and Survival

Author Malcolm Crockett releases a powerful auto-ethnographic narrative exposing institutional silence while celebrating resilience, solidarity, and truth.

In a time when institutions across the world are being called to account for past injustices, No Backup – A Set Up and More arrives as a timely, unflinching, and deeply human work. Malcolm Crockett’s book offers readers an intimate yet far-reaching exploration of what it means to live and work ethically inside systems that quietly withdraw protection, legitimacy, and safety from those deemed “other.”

Part memoir, part social history, and part literary narrative, No Backup – A Set Up and More traces the author’s journey from childhood illness and cultural displacement to professional life as a young gay social worker navigating institutional hostility. The narrative also speaks to how a young social worker coped with the residual impacts of the RCMP and Canadian government’s multi-decade involvements with the Great Purge of gays and lesbians in the Diplomatic Corps, the Civil Service, and the Canadian Military.

Adding an unexpected historical thread, Crockett notes that, as a youth, he worked closely with Tommy Douglas, Kiefer Sutherland’s grandfather and the founder of Canada’s national Medicare system. Rather than focusing on a single grievance, Crockett reveals a culture, one shaped by enforced silence, normalized prejudice, and the quiet expectation that some lives are more expendable than others.

With clarity, intelligence, and moments of sharp humor, Crockett examines how discrimination often operates not through dramatic confrontation, but through denial of support, isolation, and strategic neglect. The book’s title itself reflects this reality: “no backup” is not only a literal absence of protection, but a metaphor for institutional abandonment.

“No Backup is about what happens when doing the right thing comes with risk,” Crockett notes.

“It’s about learning how to survive with integrity when the system refuses to stand behind you.”

The book's power largely comes from its depiction of survival as something that has to be actively learned. As a part of the resistance and endurance arsenal, Crockett brings up the unions, the mentors, the allies, and even writing. None of these, however, wipe away the harm, but they enable survival and give it a sense of purpose. The story, through the author's own experience and his keen eye, shows how resilience becomes possible when one is surrounded by a supportive community, using one's wits, and being constantly aware of oneself.

No Backup – A Set Up and More gives readers both information and a chance to think. People who care about social justice, labor movements, LGBTQ+ history, and Canadian culture will find the book interesting and helpful. People who work in social work, public service, and advocacy will be familiar with the ethical issues discussed in the book, but general readers will enjoy how easy it is to read and how it tells a story.

In the end, No Backup – A Set Up and More is a book about voice: how it is silenced, how it survives, and how it is taken back. It shows how powerful stories can be in keeping the truth alive, questioning systems, and upholding human dignity. This is not only a book about the past. It is a reminder of how easily protections can be withdrawn, and why remembering, recording, and speaking still matter.

About the Author

Malcolm Crockett is a graduate of the University of British Columbia and Carleton University, with more than thirty years of professional experience in government and social services in Canada and abroad. He has worked in New Zealand, Australia, and Southeast Asia, mentored generations of social work students, and served in leadership roles within labor and community organizations. He lives in the Cowichan Valley on Vancouver Island, where he is still involved in community history and education. No Backup – A Set Up and More is a powerful way for him to help keep stories alive that institutions used to try to silence.

Amazon: https://a.co/d/02pNx2NK

Media Contact
Company Name: BN Publishing Services
Contact Person: Malcolm Crockett
Email:Send Email
Phone: +18884066480
Country: United States
Website: https://hemingwaypublishers.com/

New Children’s Story: The Story of Sharin’ Bear

A Heartfelt Message Of Courage, Kindness, And The True Meaning Of Giving

A pleasant new story for children, The Story of Sharin’ Bear by Sharon Woods, introduces families to a lovable little cub whose journey of bravery and compassion changes him into a representation of sharing for children globally.

Entrenched in adventure, innocence, and emotional growth, this uplifting tale offers an unforgettable reminder that even the smallest acts of kindness can change a life.

What Is Sharin’ Bear About?

The​‍​‌‍​‍‌​‍​‌‍​‍‌ story features a gifted young bear who decides to go out on his own to get honey and berries for his family, a love-driven and frightened by the world kind of mission, challenged by hunger and surprising obstacles along the way.

After he misses his way, barely getting rid of the danger, and meeting with weariness, the little bear comes to a point of sorrow. His resolve, however, didn't waver even for a moment.

When he was at his lowest point, the cub was met by a kind Guardian Angel Bear who saw the inner goodness of his heart.

Understanding the noble purpose of his journey, she turned him into a teddy bear, a Sharin’ Bear, made to be loved, to love back and to share the heat of love with others for the rest of his ​‍​‌‍​‍‌​‍​‌‍​‍‌life.

A Story That Inspires Children to Share

The Story of Sharin’ Bear by Sharon Woods provides children with a touching example of empathy, responsibility, and the beauty of giving.

When Tommy finds the transformed bear and later chooses to share him with his classmates, young readers witness how love expands when it is shared.

The happy and optimistic reaction of the classroom toward Sharin Bear is a great approach towards reintroducing the topics of love, community, and inclusion.

There is also the aspect of emotional development as the story teaches the children that fear is not the case without courage, but it is the desire to continue with it since your heart is telling you to do so.

A Warm, Timeless Addition to Children’s Literature

It could not be better: the book is bedtime reading, classroom sharing, and character-building discussion all in one. The Story of Sharin’ Bear is a timeless message delivered in imaginative storytelling.

Due to its emotional nature and doable lessons, the book is a source of motivation for children to follow the example of Tommy and his classmates and be just as thoughtful and caring. They are to see, appreciate and help others.

Impact on Readers

The story is also a delight for parents, teachers, and caregivers as it brings together seamlessly the elements of adventure, moral lessons, and heartwarming instances.

Sharin’ Bear turns into a link between kids, showing them that sharing not only makes them closer friends but also helps grow their inner ​‍​‌‍​‍‌​‍​‌‍​‍‌light.

Availability

Sharon Wood’s book is ideal for schools, libraries, family collections, and character-education programs. It stands as both an appealing read-aloud story and a meaningful story for inspiring empathy in young learners.

The Story of Sharin’ Bear is now available for publishing consideration and distribution. Get your hands on this book in hardcopy, paperback, and digital formats.

Amazon: https://a.co/d/0562n8mZ

Media Contact
Company Name: BN Publishing Services
Contact Person: Sharon Woods
Email:Send Email
Phone: +18884066480
Country: United States
Website: https://hemingwaypublishers.com/

Fast-Growing Newman's Brew Combines Organic Coffee Excellence with Abandoned Animal Support Initiative

We're growing because we've tapped into something coffee drinkers genuinely want: a product they can feel great about in every way. Our organic beans are roasted fresh per order, delivering unmatched smoothness and flavor. Simultaneously, every purchase contributes to feeding abandoned animals. It's coffee that tastes exceptional and does good.

Newman's Brew is experiencing rapid expansion by delivering on dual commitments that resonate with today's conscious consumers: exceptional fresh-roasted organic coffee and meaningful support for abandoned animals. The company's growing inventory and ethical business practices demonstrate that quality and social responsibility can drive sustainable business success in the competitive specialty coffee market.

Newman's Brew is riding a wave of growth that reflects fundamental shifts in how consumers approach coffee purchasing decisions. The company's success demonstrates that today's coffee drinkers seek more than just caffeine delivery; they want products that excel in quality while supporting values-aligned businesses. By combining fresh-roasted organic coffee with support for abandoned animal feeding programs, Newman's Brew has created a value proposition that resonates powerfully with its target audience.

The rapid expansion the company is experiencing stems from a business model that refuses to compromise. While conventional coffee companies choose between operational simplicity and product excellence, Newman's Brew has invested in systems that deliver both. The fresh-per-order roasting approach requires sophisticated logistics and production planning, but the result is a product that stands dramatically apart from shelf-stable alternatives that sacrifice freshness for convenience.

The company's commitment to organic beans reflects understanding that quality begins at the source. Organic certification guarantees that beans are cultivated without synthetic pesticides, herbicides, or fertilizers, resulting in cleaner flavor profiles and supporting environmental sustainability. These beans provide the foundation for coffee that tastes as good as it should, free from chemical residues and grown in harmony with natural systems.

Newman's Brew has earned particular recognition for producing the smoothest coffee available in today's market. This smoothness represents the intersection of multiple quality factors: superior bean selection, precise roasting technique, and optimal freshness. Coffee drinkers who have struggled with harsh, acidic, or bitter brews discover in Newman's Brew a product that delivers bold flavor without the unpleasant characteristics they've come to expect from coffee.

The robust flavors showcased in Newman's Brew coffee highlight the natural notes inherent in well-grown, freshly roasted beans. These flavor characteristics often get obscured in stale coffee or poorly executed roasts. When beans are handled properly and roasted fresh, the complexity becomes apparent. Customers experience taste dimensions they may not have realized coffee could offer, from fruit and floral notes to chocolate, caramel, and spice characteristics.

As Newman's Brew's inventory continues expanding, the company is introducing customers to the remarkable diversity available in the coffee world. Different growing regions, bean varieties, and roast profiles create distinct taste experiences. This growing selection allows coffee enthusiasts to explore while ensuring that newcomers can find accessible entry points. The expanding variety reflects the company's commitment to education alongside commerce, helping customers develop more sophisticated appreciation for quality coffee.

The animal welfare component of Newman's Brew's mission adds dimension that distinguishes the brand in meaningful ways. By dedicating resources to support feeding programs for abandoned animals, the company creates impact beyond its core product. This commitment attracts customers who want their purchases to contribute to positive change, building a community of conscious consumers who feel good about every bag they buy.

The company's high ethical standards permeate every operational aspect. From sourcing relationships with responsible growers to the environmental considerations in packaging and shipping, Newman's Brew consistently chooses the path that aligns with its values. These decisions sometimes increase costs or complexity, but they result in a business that customers can trust and proudly support.

The growth trajectory Newman's Brew is following suggests that the company has identified a sustainable market position. As more coffee drinkers become educated about quality and seek brands that reflect their values, Newman's Brew is perfectly positioned to capture this expanding audience. The combination of exceptional product quality and genuine social commitment creates differentiation that mere marketing cannot replicate.

For coffee drinkers who refuse to compromise between taste, ethics, and freshness, Newman's Brew offers a solution that delivers comprehensively. The fresh-roasted organic beans provide smoothness and robust flavor that make every cup a pleasure, while the support for abandoned animals ensures that each purchase contributes to positive impact beyond personal enjoyment.

CONTACT: https://Newmansbrew.com

Media Contact
Company Name: Newman's Brew
Contact Person: John Watson
Email:Send Email
Country: United States
Website: https://newmansbrew.com

Unpair Introduces a Patent-Pending Symmetrical Footwear System That Eliminates Left and Right

Founded by Taiwanese fashion designer turned inventor Hui Min Yang, Unpair reimagines footwear through symmetry, interchangeability, and universal form.

Houston, TX - February 19th, 2026 - Unpair officially announces a patent-pending symmetrical footwear system that challenges centuries of left-right shoe design. For centuries, footwear has followed a fixed rule: one shoe for the left foot and one for the right.

Unpair challenges that convention by introducing a patent-pending symmetrical footwear system designed to function without left-right distinction. The project presents a universal shoe form that can be worn interchangeably, eliminating the structural divide that has defined footwear design for generations.

The System & Reversible Toe Structure

At the core of Unpair is a precisely engineered symmetrical architecture — including a balanced outsole and neutral last geometry designed for ambidextrous wear.

Supporting this structure is a patent-pending reversible toe insert system. Positioned between the foot and the interior front of the shoe, the insert fills the remaining toe space dynamically, allowing the same shoe to comfortably accommodate either foot orientation.

This modular and reversible component enables a unified shoe structure without compromising alignment, stability, or comfort.

From Fashion to Innovation

Unpair was founded, invented, and designed by Hui Min Yang, a Taiwanese fashion designer based in Texas who transitioned into product innovation and entrepreneurship.

Known professionally as May Yang, she began exploring symmetrical footwear as a design experiment. What started as a conceptual study evolved into a patent-pending innovation and a startup focused on rethinking the fundamentals of shoe construction.

By removing the traditional left-right paradigm, Unpair opens a broader conversation about efficiency, modularity, and the future of adaptable consumer design systems.

About Unpair

Unpair is a patent-pending footwear innovation startup founded by Hui Min Yang (May Yang).

Headquartered in Texas, the company explores universal shoe architecture, interchangeable internal systems, and ambidextrous design principles — introducing a new framework for how footwear can be structured, manufactured, and experienced.

Media Contact
Company Name: UNPAIR SHOE
Contact Person: Hui Min Yang (May Yang)
Email:Send Email
Country: United States
Website: https://unpairshoes.com/

Top Realtor in Vienna, VA, Marks 18th Year Serving Northern Virginia Market

Vienna, VA - Andrea Woodhouse, an associate broker at Maple Ave Living, celebrates a significant milestone in 2026, marking 18 years since obtaining her real estate license in 2009. Her journey began when frustration with her own home sale sparked a passion for helping others navigate the real estate process with greater ease and success.

Over nearly two decades, Andrea Woodhouse has distinguished herself as a real estate agent in Vienna, VA who consistently ranks among the top 2% of agents in volume across the Northern Virginia market. Her impressive track record includes facilitating the second most expensive condominium sale in Washington, DC during 2025—a $6 million transaction that showcases her ability to serve clients at every price point with equal dedication and expertise.

As one of the top Vienna, VA Realtors, Andrea has built her success on a foundation of mathematical precision combined with genuine empathy for the emotional aspects of buying and selling homes. Her background in math informs her meticulous approach to pricing strategy and market analysis, while her understanding that real estate decisions are deeply personal ensures clients receive both analytical rigor and compassionate guidance throughout their journey.

Andrea Woodhouse, recognized by many as a trusted Realtor agent in Vienna, VA, credits her longevity to authenticity and consistency. "Be authentic," she advises. "Find what works for you and stay consistent. Success looks different for everyone, and that's what makes this business so rewarding."

The growth of Andrea's business reflects her commitment to excellence. After years as a solo agent, she formed Maple Ave Living in 2019 with Rebecca Rushforth, expanding to a team of five women united in delivering concierge-level service. As an experienced real estate listing agent in Vienna, VA licensed across Virginia, DC, and Maryland, Andrea continues balancing professional growth with personal priorities. "Being a business owner allows me the flexibility to travel, spend time with my family, and help others reach their goals," she says. "It's a privilege to be part of someone's story when they are buying or selling a home."

Those seeking knowledgeable representation can visit www.compass.com/agents/andrea-woodhouse to begin their real estate journey today.

Media Contact
Company Name: Andrea Woodhouse | Real Estate Agent in Vienna & Oakton, VA
Contact Person: Andrea Woodhouse
Email:Send Email
Address:144 Church St NW suite 103
City: Vienna
State: VA 22180
Country: United States
Website: https://www.compass.com/agents/andrea-woodhouse/

Rett Syndrome Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “Rett Syndrome Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Rett Syndrome pipeline landscape. It covers the Rett Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rett Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Rett Syndrome Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/rett-syndrome-pipeline-insight

Key Takeaways from the Rett Syndrome Pipeline Report

• In January 2026, Neurogene Inc. announced a phase 1/2 study and is an open-label, baseline-controlled, multicenter, single-arm study designed to assess the efficacy, safety, and tolerability of administration of NGN401, an adeno-associated viral vector serotype 9 (AAV9) using Neurogene's proprietary transgene regulation technology. NGN-401 contains a full-length human MECP2 gene and is designed to express therapeutic levels of the MeCP2 protein while avoiding overexpression.
• DelveInsight’s Rett Syndrome Pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Rett Syndrome treatment.
• The leading Rett Syndrome Companies such as Xuanwu Hospital, Beijing, Aegle Therapeutics, ZEO ScientifiX Inc., Direct Biologics LLC, Rion Inc. and others.
• Promising Rett Syndrome Therapies such as Fingolimod (FTY720), Bionetide, TSHA-102, NNZ-2566, NTI164, ANAVEX2-73 and others.

Want to know which companies are leading innovation in Rett Syndrome? Dive into the full pipeline insights @ Rett Syndrome Clinical Trials Assessment

The Rett Syndrome Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Rett Syndrome Pipeline Report also highlights the unmet needs with respect to the Rett Syndrome.

Rett Syndrome Overview

Rett syndrome is a rare, severe neurodevelopmental disorder that primarily affects girls and leads to progressive impairments in motor skills, communication, cognition, and autonomic function. It is most commonly caused by mutations in the MECP2 gene on the X chromosome, a gene essential for normal brain development and synaptic function.

Rett Syndrome Emerging Drugs

• Blarcamesine: Anavex Life Sciences Corp

Blarcamesine is a small molecule, orally administered drug that restores cellular homeostasis by targeting SIMGAR1 and muscarinic receptors that is pivotal to restoring cellular homeostasis and promoting neuroplasticity. The drug candidate has received Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation from the FDA. Currently, the drug is in Phase III stage of its development for the treatment of Rett syndrome.

• TSHA-102: Taysha GTx

TSHA-102 is a self-complementary intrathecal delivered AAV9 gene transfer therapy in clinical evaluation. TSHA-102 is constructed from a neuronal specific promoter, MECP2, a gene essential for neuronal and synaptic function in the brain. TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) platform designed to regulate cellular MECP2 expression. TSHA-102 has received Orphan Drug and Rare Pediatric Disease designations from the United States (U.S.) Food and Drug Administration (FDA) and has been granted Orphan Drug designation from the European Commission. Currently, the drug is in Phase I/II stage of its development for the treatment of Rett syndrome.

• NGN-401: Neurogene

NGN-401 is an investigational AAV9 gene therapy being developed as a one line treatment for Rett syndrome. It is the first clinical candidate to deliver the full-length human MECP2 gene under the control of Neurogene’s EXACT technology. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with Rett Syndrome.

The Rett Syndrome Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Rett Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rett Syndrome Treatment.
• Rett Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Rett Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rett Syndrome market.

If you’re tracking ongoing Rett Syndrome Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Rett Syndrome Treatment Drugs

Rett Syndrome Companies

Xuanwu Hospital, Beijing, Aegle Therapeutics, ZEO ScientifiX Inc., Direct Biologics LLC, Rion Inc. and others.

Rett Syndrome Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Rett Syndrome Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the Rett Syndrome Pipeline Report covers it all – check it out now @ Rett Syndrome Market Drivers and Barriers, and Future Perspectives

Scope of the Rett Syndrome Pipeline Report

• Coverage- Global
• Rett Syndrome Companies- Xuanwu Hospital, Beijing, Aegle Therapeutics, ZEO ScientifiX Inc., Direct Biologics LLC, Rion Inc. and others.
• Rett Syndrome Therapies- Fingolimod (FTY720), Bionetide, TSHA-102, NNZ-2566, NTI164, ANAVEX2-73 and others.
• Rett Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Rett Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in oncology research – discover what’s next for the Rett Syndrome treatment landscape in this detailed analysis @ Rett Syndrome Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Rett Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutics Assessment
6. Rett Syndrome – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Blarcamesine: Anavex Life Sciences Corp
9. Mid Stage Products (Phase II)
10. Early Stage Products (Phase I/II)
11. TSHA-102: Taysha GTx
12. Preclinical and Discovery Stage Products
13. Inactive Products
14. Rett Syndrome Key Companies
15. Rett Syndrome Key Products
16. Rett Syndrome- Unmet Needs
17. Rett Syndrome- Market Drivers and Barriers
18. Rett Syndrome- Future Perspectives and Conclusion
19. Rett Syndrome Analyst Views
20. Rett Syndrome Key Companies
21. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/rett-syndrome-pipeline-insight

Chronic Rhinosinusitis with Nasal Polyps Clinical Trial Pipeline Expands as 8+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Chronic Rhinosinusitis with Nasal Polyps Pipeline Insight 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in the Chronic Rhinosinusitis with Nasal Polyps pipeline landscape. It covers the Chronic Rhinosinusitis with Nasal Polyps Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Rhinosinusitis with Nasal Polyps Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Chronic Rhinosinusitis with Nasal Polyps Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/chronic-rhinosinusitis-with-nasal-polyps-pipeline-insight

Key Takeaways from the Chronic Rhinosinusitis with Nasal Polyps Pipeline Report

• On February 18, 2026- Sanofi initiated a study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical study (also referred to as the parent study ACT18207).
• On February 12, 2026- Eli Lilly and Company announced a phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Participants With Chronic Rhinosinusitis With Nasal Polyps on Background Intranasal Corticosteroids.
• On February 11, 2026- AstraZeneca conducted a phase IIIb study is to describe changes from baseline in (1) participant-reported nasal congestion as evaluated by the nasal congestion score (NCS) and (2) participant-reported sino-nasal symptoms as evaluated by sino-nasal outcome test, 22 item (SNOT-22) following initiation of tezepelumab treatment.
• DelveInsight’s Chronic Rhinosinusitis with Nasal Polyps Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Chronic Rhinosinusitis with Nasal Polyps treatment.
• The leading Chronic Rhinosinusitis with Nasal Polyps Companies such as Keymed Biosciences Co. Ltd, GlaxoSmithKline, Genrix (Shanghai) Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co Ltd and others.
• Promising Chronic Rhinosinusitis with Nasal Polyps Therapies such as Tezepelumab, Verekitug (UPB-101), GR1802, Dupilumab SAR231893, Mepolizumab, lunsekimig, Itepekimab (SAR440340), CM310, Omalizumab and others.

Want to know which companies are leading innovation in Chronic Rhinosinusitis with Nasal Polyps? Dive into the full pipeline insights @ Chronic Rhinosinusitis with Nasal Polyps Clinical Trials Assessment

The Chronic Rhinosinusitis with Nasal Polyps Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Chronic Rhinosinusitis with Nasal Polyps Pipeline Report also highlights the unmet needs with respect to the Chronic Rhinosinusitis with Nasal Polyps.

Chronic Rhinosinusitis with Nasal Polyps Overview

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition affecting the nasal passages and sinuses, characterized by the growth of benign polyps. These polyps, which are soft, painless, and non-cancerous, arise from the mucous membranes and can obstruct the nasal airways, leading to significant breathing difficulties. Patients often experience symptoms such as nasal congestion, a reduced sense of smell, facial pain or pressure, and nasal discharge. The condition is distinct from other forms of chronic rhinosinusitis due to the presence of these polyps, which play a critical role in the chronic nature and severity of the disease.

Chronic Rhinosinusitis with Nasal Polyps Emerging Drugs Profile

• GSK3511294: GlaxoSmithKline

GSK3511294 (depemokimab) is a novel investigational treatment being studied for chronic rhinosinusitis with nasal polyps (CRSwNP). Depemokimab is thought to work by inhibiting interleukin-5 (IL-5), a key cytokine involved in the type 2 inflammatory response that drives eosinophilic inflammation in CRSwNP. Blocking IL-5 may help reduce polyp size and improve symptoms. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Chronic rhinosinusitis with nasal polyps.

• CM326: Keymed Biosciences Co.Ltd

CM326 is a monoclonal antibody being investigated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The rationale for targeting thymic stromal lymphopoietin (TSLP) with CM326 is based on its role in the pathogenesis of CRSwNP. TSLP is a key cytokine involved in the initiation and maintenance of type 2 inflammatory responses, which are characteristic of CRSwNP. Currently, the drug is in the Phase II stage of development to treat Chronic rhinosinusitis with nasal polyps.

If you’re tracking ongoing Chronic Rhinosinusitis with Nasal Polyps Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Chronic Rhinosinusitis with Nasal Polyps Treatment Drugs

The Chronic Rhinosinusitis with Nasal Polyps Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Rhinosinusitis with Nasal Polyps with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Rhinosinusitis with Nasal Polyps Treatment.
• Chronic Rhinosinusitis with Nasal Polyps Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Rhinosinusitis with Nasal Polyps Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Rhinosinusitis with Nasal Polyps market.

Chronic Rhinosinusitis with Nasal Polyps Companies

Keymed Biosciences Co., Ltd., GlaxoSmithKline, Genrix (Shanghai) Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co Ltd and others

Chronic Rhinosinusitis with Nasal Polyps Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Chronic Rhinosinusitis with Nasal Polyps Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Chronic Rhinosinusitis with Nasal Polyps Pipeline Report covers it all – check it out now @ Chronic Rhinosinusitis with Nasal Polyps Market Drivers and Barriers, and Future Perspectives

Scope of the Chronic Rhinosinusitis with Nasal Polyps Pipeline Report

• Coverage- Global
• Chronic Rhinosinusitis with Nasal Polyps Companies- Keymed Biosciences Co. Ltd, GlaxoSmithKline, Genrix (Shanghai) Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co Ltd and others.
• Chronic Rhinosinusitis with Nasal Polyps Therapies- Tezepelumab, Verekitug (UPB-101), GR1802, Dupilumab SAR231893, Mepolizumab, lunsekimig, Itepekimab (SAR440340), CM310, Omalizumab and others.
• Chronic Rhinosinusitis with Nasal Polyps Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Rhinosinusitis with Nasal Polyps Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Chronic Rhinosinusitis with Nasal Polyps Treatment landscape in this detailed analysis @ Chronic Rhinosinusitis with Nasal Polyps Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Chronic Rhinosinusitis with Nasal Polyps: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Rhinosinusitis with Nasal Polyps – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. GSK3511294: GlaxoSmithKline
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CM310: Keymed Biosciences
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic Rhinosinusitis with Nasal Polyps Key Companies
21. Chronic Rhinosinusitis with Nasal Polyps Key Products
22. Chronic Rhinosinusitis with Nasal Polyps- Unmet Needs
23. Chronic Rhinosinusitis with Nasal Polyps- Market Drivers and Barriers
24. Chronic Rhinosinusitis with Nasal Polyps- Future Perspectives and Conclusion
25. Chronic Rhinosinusitis with Nasal Polyps Analyst Views
26. Chronic Rhinosinusitis with Nasal Polyps Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-pipeline-insight

Stargardt Disease Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Stargardt Disease Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Stargardt Disease pipeline landscape. It covers the Stargardt Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Stargardt Disease Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight

Key Takeaways from the Stargardt Disease Pipeline Report

• In January 2026, AAVantgarde Bio Srl announced a 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.
• In January 2026, Belite Bio Inc. initiated a Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects With Stargardt Disease and a Phase 2/3 Randomized, Double-masked, and Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Tinlarebant in Subjects With Stargardt Disease
• DelveInsight’s Stargardt Disease Pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Stargardt Disease treatment.
• The leading Stargardt Disease Companies such as Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio, and others.
• Promising Stargardt Disease Therapies such as Emixustat, OCU410ST, tinlarebant, SB-007, STG-001, ALK-001, Emixustat, ACDN-01, VG801, and others.

Want to know which companies are leading innovation in Stargardt Disease? Dive into the full pipeline insights @ Stargardt Disease Clinical Trials Assessment

The Stargardt Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Stargardt Disease Pipeline Report also highlights the unmet needs with respect to the Stargardt Disease.

Stargardt Disease Overview

Stargardt disease, stemming from a hereditary anomaly in the ABCA4 gene, manifests when both copies of this gene, one from each parent, carry mutations. This genetic defect leads to the accumulation of lipofuscin, a metabolic waste product, within the retina. Normally, the retina efficiently clears away this material, but in Stargardt disease, this clearance process is hindered, resulting in damage to retinal cells and subsequent vision loss. The severity of the condition varies widely among individuals due to the diverse spectrum of mutations within the ABCA4 gene.

Stargardt Disease Emerging Drugs Profile

• Tinlarebant: Belite Bio

Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in STGD1 and also contribute to disease progression in GA, or advanced Dry AMD. Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol-binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, Tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the US, and Orphan Drug Designation in the US, Europe, and Japan for the treatment of STGD1. Currently, the drug is in the Phase III stage of its clinical trial for the treatment of Stargardt disease.

• KIO-301: Kiora Pharmaceuticals

KIO-301 is a molecular photoswitch designed to confer light-sensing capabilities to Retinal Ganglion Cells (RGCs). It targets patients with inherited retinal diseases where mutations lead to photoreceptor death, causing vision loss. Unlike healthy eyes where photoreceptors perform light detection, KIO-301 selectively enters RGCs downstream of degenerated photoreceptors. Inside RGCs, it interacts with voltage-gated ion channels. When exposed to light, KIO-301 changes shape, altering current flow and activating neurons to signal the brain. Removal of light causes KIO-301 to revert to its original shape, halting signaling. Essentially, KIO-301 acts as a light switch within the eye, restoring light sensitivity in patients with retinal degeneration. Currently, the drug is in the Phase II stage of its clinical trial for the treatment of Stargardt disease.

• OCU410: Ocugen

OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene. The RORA protein plays an important role in lipid metabolism, reducing lipofuscin deposits and oxidative stress, and demonstrates an anti-inflammatory role in-vitro and in-vivo (animal model) studies. These results demonstrate the ability for OCU410 to target multiple pathways linked with dAMD pathophysiology. Ocugen is developing AAV-RORA as a one-time gene therapy for the treatment of GA. Currently, the drug is in the Phase I/II stage of its clinical trial for the treatment of stargardt disease.

If you’re tracking ongoing Stargardt Disease Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Stargardt Disease Treatment Drugs

Stargardt Disease Companies

Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio and others.

The Stargardt Disease Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Stargardt Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Stargardt Disease Treatment.
• Stargardt Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Stargardt Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Stargardt Disease market.

Stargardt Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Stargardt Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Stargardt Disease Pipeline Report covers it all – check it out now @ Stargardt Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Stargardt Disease Pipeline Report

• Coverage- Global
• Stargardt Disease Companies- Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio and others.
• Stargardt Disease Therapies- Emixustat, OCU410ST, tinlarebant, SB-007, STG-001, ALK-001, Emixustat, ACDN-01, VG801 and others.
• Stargardt Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Stargardt Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Stargardt Disease Treatment landscape in this detailed analysis @ Stargardt Disease Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Stargardt disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Stargardt disease – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Tinlarebant: Belite Bio
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. KIO-301: Kiora Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. OCU410: Ocugen
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Stargardt disease Key Companies
21. Stargardt disease Key Products
22. Stargardt disease - Unmet Needs
23. Stargardt disease - Market Drivers and Barriers
24. Stargardt disease - Future Perspectives and Conclusion
25. Stargardt disease Analyst Views
26. Stargardt disease Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/stargardt-disease-stgd-pipeline-insight